Atay Oguzhan sold $523K of BLLN (indirect holdings)

Atay Oguzhan (Chairman and CEO) sold 5,332 indirectly-held shares of BillionToOne, Inc. (BLLN) at $98.00 ($0.52M total) across 2 trades on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Atay Oguzhan
Published Sep 16, 2026, 10:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 10:46 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$BLLN
Neutral
medium confidence
Mentioned
$BLLN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLLNNeutralLow
01

Why it matters

The sale is modest and likely already priced in; traders should not adjust positions based solely on this filing.

02

Market read

Low relevance; typical insider sale with limited market effect.

03

What to watch

Potential upcoming financing needs or dilution not disclosed.

Relevance 4/10Novelty 5/10Timing: post‑market 2026‑09‑14

Background

Form 4 filing discloses insider transactions; BLLN is a micro‑cap biotech.

Company-level read

Ticker impact

$BLLNNeutralMedium confidence
Context

Chairman and CEO sold 5,332 shares for $522,536 via a 10b5-1 plan on 2026-09-14.

Expected impact

Limited short-term pressure; unlikely to move price materially.

Evidence & confidence

The transaction is a routine 10b5-1 sale of less than $1M, typical for insiders; market impact is expected to be minimal.

Market effects

No direct sector impact; biotech sector unchanged.

U.S. market only; no regional ripple.

Not globally relevant.

Counterpoint

If the insider holds significant knowledge, the sale could hint at upcoming challenges.

Key entities

  • BillionToOne, Inc.

    Biotech firm listed on NASDAQ under ticker BLLN.

  • Atay Oguzhan

    Chairman and CEO of BillionToOne, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Why is BillionToOne stock sliding today?

BillionToOne stock fell 6.2% in pre-market trading after Fuzzy Panda Research disclosed a short position and alleged regulatory and billing misconduct, including overbilling and potential unlawful practices. The company's stock had already declined from its 52-week high of $150.44, and broader market pressures contributed to the decline.

$BLLNMed

BillionToOne shares slide in pre-market trading following short-seller report

BillionToOne (BLLN) shares fell 6% premarket after a short-seller report alleged improper billing, undisclosed regulatory scrutiny, and clinical claim weaknesses. Fuzzy Panda Research, which holds a short position, cited FOIA records, anonymous sources, and billing data. The report claims potential EBITDA reduction of 80% and False Claims Act penalties up to $1.2B. BillionToOne has not responded.

$BLLNMed

BillionToOne: Q3 Earnings Snapshot

BillionToOne (BLLN) reported Q3 earnings of $17.4M, or 32 cents per share, beating estimates of 16 cents. Revenue was $123M, exceeding forecasts of $116.2M. The company expects full-year revenue between $460M and $470M. Shares have risen 39% YTD.